- Home
- ASBP
as 04-18-2025 1:31pm EST
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tract.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 26.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 216.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.40 - $15.80 | Next Earning Date: | 05-24-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Aspire Biopharma Holdings Inc. Common Stock News
ASBP Breaking Stock News: Dive into ASBP Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream
ACCESS Newswire
5 days ago
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17
ACCESS Newswire
8 days ago
Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement
ACCESS Newswire
10 days ago
Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
ACCESS Newswire
a month ago
Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin
ACCESS Newswire
a month ago
Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform
Newsfile
a month ago
An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation
ACCESS Newswire
2 months ago
Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement
Compare ASBP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ASBP Aspire Biopharma Holdings Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.